Tango Therapeutics Stock Performance

TNGX Stock  USD 12.51  0.56  4.69%   
On a scale of 0 to 100, Tango Therapeutics holds a performance score of 12. The entity has a beta of 0.092, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Tango Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tango Therapeutics is expected to be smaller as well. Please check Tango Therapeutics' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Tango Therapeutics' existing price patterns will revert.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Tango Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating technical and fundamental indicators, Tango Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
4.69
Five Day Return
7.66
Year To Date Return
40.09
Ten Year Return
22.29
All Time Return
22.29
1
Retail Trends How interest rate cuts could boost Tango Therapeutics Inc stock - Recession Risk Fast Exit Strategy with Risk Control - B NI V
12/01/2025
2
Disposition of 477401 shares by Third Rock Ventures Iv, L.p. of Tango Therapeutics at 10.152 subject to Rule 16b-3
12/18/2025
3
Will Tango Therapeutics Inc. stock benefit from commodity prices - July 2025 Trends AI Driven Stock Reports -
12/19/2025
4
Insider Trading
01/02/2026
5
Biotech finance veteran joins cancer drug developers board - Stock Titan
01/05/2026
6
Tango Therapeutics Announces CEO Transition Barbara Weber to Retire, Malte Peters Appointed Successor
01/08/2026
7
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data - Investing.com
01/12/2026
8
Tango Therapeutics Valuation Check After Leadership Reshuffle And Strong Recent Share Price Performance
01/15/2026
9
A Look At Tango Therapeutics Valuation After CEO Transition And Strong Recent Share Price Returns
01/22/2026
10
Acquisition by Crystal Adam of 47460 shares of Tango Therapeutics subject to Rule 16b-3
02/02/2026
11
Disposition of 201 shares by Crystal Adam of Tango Therapeutics at 12.8971 subject to Rule 16b-3
02/03/2026
12
Expert Outlook Tango Therapeutics Through The Eyes Of 4 Analysts - Benzinga
02/06/2026
Begin Period Cash Flow69.8 M
Total Cashflows From Investing Activities86.1 M

Tango Therapeutics Relative Risk vs. Return Landscape

If you would invest  793.00  in Tango Therapeutics on November 10, 2025 and sell it today you would earn a total of  458.00  from holding Tango Therapeutics or generate 57.76% return on investment over 90 days. Tango Therapeutics is currently generating 0.8825% in daily expected returns and assumes 5.5686% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Tango, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Tango Therapeutics is expected to generate 6.85 times more return on investment than the market. However, the company is 6.85 times more volatile than its market benchmark. It trades about 0.16 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of risk.

Tango Therapeutics Target Price Odds to finish over Current Price

The tendency of Tango Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 12.51 90 days 12.51 
about 5.32
Based on a normal probability distribution, the odds of Tango Therapeutics to move above the current price in 90 days from now is about 5.32 (This Tango Therapeutics probability density function shows the probability of Tango Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Tango Therapeutics has a beta of 0.092. This usually implies as returns on the market go up, Tango Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Tango Therapeutics will be expected to be much smaller as well. Additionally Tango Therapeutics has an alpha of 0.803, implying that it can generate a 0.8 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Tango Therapeutics Price Density   
       Price  

Predictive Modules for Tango Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tango Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
6.1211.7317.34
Details
Intrinsic
Valuation
LowRealHigh
6.1311.7417.35
Details
Naive
Forecast
LowNextHigh
6.0811.6917.31
Details
8 Analysts
Consensus
LowTargetHigh
13.0814.3815.96
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Tango Therapeutics. Your research has to be compared to or analyzed against Tango Therapeutics' peers to derive any actionable benefits. When done correctly, Tango Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Tango Therapeutics.

Tango Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Tango Therapeutics is not an exception. The market had few large corrections towards the Tango Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Tango Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Tango Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.80
β
Beta against Dow Jones0.09
σ
Overall volatility
1.61
Ir
Information ratio 0.13

Tango Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tango Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tango Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Tango Therapeutics is way too risky over 90 days horizon
Tango Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 42.07 M. Net Loss for the year was (130.3 M) with loss before overhead, payroll, taxes, and interest of (67.5 M).
Tango Therapeutics currently holds about 416.36 M in cash with (131.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.73.
Over 100.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Expert Outlook Tango Therapeutics Through The Eyes Of 4 Analysts - Benzinga

Tango Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tango Stock often depends not only on the future outlook of the current and potential Tango Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tango Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding109.2 M
Cash And Short Term Investments257.9 M

Tango Therapeutics Fundamentals Growth

Tango Stock prices reflect investors' perceptions of the future prospects and financial health of Tango Therapeutics, and Tango Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tango Stock performance.

About Tango Therapeutics Performance

Evaluating Tango Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Tango Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tango Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.47)(0.50)
Return On Capital Employed(0.60)(0.63)
Return On Assets(0.47)(0.50)
Return On Equity(0.59)(0.62)

Things to note about Tango Therapeutics performance evaluation

Checking the ongoing alerts about Tango Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tango Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Tango Therapeutics is way too risky over 90 days horizon
Tango Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 42.07 M. Net Loss for the year was (130.3 M) with loss before overhead, payroll, taxes, and interest of (67.5 M).
Tango Therapeutics currently holds about 416.36 M in cash with (131.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.73.
Over 100.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Expert Outlook Tango Therapeutics Through The Eyes Of 4 Analysts - Benzinga
Evaluating Tango Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Tango Therapeutics' stock performance include:
  • Analyzing Tango Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tango Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Tango Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Tango Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tango Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Tango Therapeutics' stock. These opinions can provide insight into Tango Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Tango Therapeutics' stock performance is not an exact science, and many factors can impact Tango Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.